Making the Case for a Digital Revolution in Market Access
As pharmaceutical companies evolve toward digital-first commercial models, U.S. market access strategies seem to be lagging in the digital revolution. Companies face many...
As pharmaceutical companies evolve toward digital-first commercial models, U.S. market access strategies seem to be lagging in the digital revolution. Companies face many...
Non-adherence to prescribed therapy can create extraordinary risks for patients. Even when provided with correct diagnoses and effective treatment plans, patients can often...
There may be no greater threat to patient outcomes than the current barriers to therapy access—especially for specialty medications.
Growth in healthcare technology began with the HITECH (Health Information Technology for Economic and Clinical Health) Act of 2009 and has grown significantly over the years....
Every day, patients switch to new therapies because of disease progression, side effects, affordability or other factors—potentially delaying patient recoveries, negatively...
Over the past decade, pharma has made significant investments in real-world data (RWD) and in analytics/insights generated from that data. At OptimizeRx, we’re applying this...
It’s a problem with an enormous impact on patients that has been nearly impossible to solve: Brand-eligible patients are out there, but they’ve been misdiagnosed or, even...
Despite incredible advances in the availability of real-world data (RWD) and AI applications, many tech-savvy brand...
At the recent Re:Imagine Pharma Marketing virtual conference, I was excited to present on how...
In our series on the challenges MS patients face in starting and staying on therapy, we’ve explored three key areas...
In our first two blog posts on challenges related to multiple sclerosis (MS) treatment, we addressed the need to build awareness...
In our initial blog post on challenges related to multiple sclerosis (MS) treatments, we discussed the first barrier, which is...